Abstract
Inhibition of insulin-like growth factor-1 receptor (IGF-1R) signaling represents an attractive therapeutic strategy for cancer treatment. A first-generation IGF-1R inhibitor (R)-4-(3-(3-chlorophenyl)-3-hydroxypropyl)-3-(4-methyl-6-morpholino-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-536924), however, was associated with potent CYP3A4 induction mediated by pregnane X receptor (PXR; NR1I2) transactivation. Structural activity-based modification led to the synthesis of 4-(1-(2-(4-((2-(4-chloro-1H-pyrazol-1-yl)ethyl)amino)-2-oxo-1,2-dihydropyridin-3-yl)-4-methyl-1H-benzo[d]imidazol-6-yl)piperidin-4-yl) piperazine-1-carboxylate (BMS-665351) with no PXR activity while maintaining its ability to inhibit IGF-1R. However, BMS-665351 significantly induces CYP3A4 expression in human primary hepatocytes (HPHs). Here, we report a novel nonclassical constitutive androstane receptor (CAR; NR1I3)-related pathway of BMS-665351-mediated CYP3A4 induction. BMS-665351 treatment resulted in the significant induction of CYP3A4 in HPHs and HepG2 cells, but failed to activate either PXR or CAR in cell-based reporter assays. Moreover, BMS-665351 at concentrations that induce CYP3A4 expression was unable to translocate human CAR from the cytoplasm to the nucleus of HPHs, which represents the initial step of CAR activation. Nevertheless, quantitative polymerase chain reaction analysis demonstrated that BMS-665351 significantly enhanced the expression of CYP3A4 in CAR- but not PXR-transfected HepG2 and Huh7 cells. It is noteworthy that BMS-665351 selectively induced the expression of CAR but not PXR in all tested hepatic cell systems. Synergistic induction of CYP3A4 was observed in HPHs cotreated with BMS-665351 and prototypical activators of CAR but not PXR. In summary, our results indicate that BMS-665351-mediated induction of CYP3A4 is CAR-dependent, but BMS-665351 itself is not a typical activator of either CAR or PXR, rather it functions as a selective inducer of CAR expression and increases CYP3A4 through a noncanonical CAR-related mechanism.
Footnotes
This research was supported by a research agreement with Bristol-Meyer Squibb; and funding from the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [Grant DK061652] (to H.W.).
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
-
ABBREVIATIONS:
- IGF-1R
- insulin-like growth factor-1 receptor
- Act.D
- actinomycin D
- CAR
- constitutive androstane receptor
- hCAR
- human CAR
- Ad/EYFP-hCAR
- adenovirus-expressing enhanced yellow florescent protein tagged hCAR
- CHX
- cycloheximide
- DDI
- drug-drug interaction
- DMSO
- dimethyl sulfoxide
- GAPDH
- glyceraldehyde-3-phosphate dehydrogenase
- GR
- glucocorticoid receptor
- HPH
- human primary hepatocyte
- CITCO
- 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde-O-(3,4-dichlorobenzyl) oxime
- PB
- phenobarbital
- PXR
- pregnane X receptor
- hPXR
- human PXR
- PXRE
- proximal everted repeat-6 element
- RIF
- rifampicin
- PK11195
- 1-(2-chlorophenyl-N-methylpropyl)-3-isoquinoline-carboxamide
- RT-PCR
- reverse transcription-polymerase chain reaction
- VDR
- vitamin D receptor
- XREM
- xenobiotic-responsive enhancer module
- BMS-665351
- 4-(1-(2-(4-((2-(4-chloro-1H-pyrazol-1-yl)ethyl)amino)-2-oxo-1,2-dihydropyridin-3-yl)-4-methyl-1H-benzo[d]imidazol-6-yl)piperidin-4-yl)piperazine-1-carboxylate
- BMS-536924
- (R)-4-(3-(3-chlorophenyl)-3-hydroxypropyl)-3-(4-methyl-6-morpholino-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one.
- Received October 7, 2011.
- Accepted December 6, 2011.
- Copyright © 2012 by The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|